Fidelity Investments’s Bright Minds Biosciences DRUG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.81M Buy
56,476
+48,625
+619% +$3.43M ﹤0.01% 2666
2026
Q2
$551K Buy
7,851
+7,032
+859% +$552K ﹤0.01% 3253
2026
Q1
$59.8K Sell
819
-292
-26% -$23.5K ﹤0.01% 4041
2025
Q4
$86.7K Buy
1,111
+460
+71% +$30.7K ﹤0.01% 3833
2025
Q3
$39.5K Buy
651
+572
+724% +$22.2K ﹤0.01% 4083
2025
Q2
$2.06K Buy
+79
New +$2.37K ﹤0.01% 4857

Other funds holding DRUG

Fidelity Investments's DRUG Position: Q3 2026 in Review

Fidelity Investments increased its Bright Minds Biosciences (DRUG) stake by 619% in Q3 2026, buying an estimated $3.43M and bringing the position to 56,476 shares worth $2.81M. The position accounts for ﹤0.01% of the portfolio, ranked #2666.

Fidelity Investments first reported a position in DRUG in Q2 2025 and has held it in 6 quarters since. 109 funds tracked by Wall St. Rank hold DRUG as of Q3 2026.

  • Fidelity Investments held 56,476 shares of Bright Minds Biosciences worth $2.81M as of Q3 2026.
  • Fidelity Investments bought 48,625 Bright Minds Biosciences shares in Q3 2026, an estimated $3.43M.
  • Bright Minds Biosciences made up ﹤0.01% of Fidelity Investments's portfolio in Q3 2026, its #2666 holding.
  • Fidelity Investments first reported a position in Bright Minds Biosciences in Q2 2025 and has held it in 6 quarters since.
  • 109 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q3 2026.

Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.